


# Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells

## Graphical abstract



## Authors

Peter D. Krueger, Michael F. Goldberg, Sung-Wook Hong, ..., Dmitri I. Kotov, Thamothersampillai Dileepan, Marc K. Jenkins

## Correspondence

jenki002@umn.edu

## In brief

CD4<sup>+</sup> T cells are critical for protection from phagosomal bacteria but not acute viruses. *Krueger et al.* find that although both infections drive formation of weakly protective Tfh and IL-12 independent Th1 cells, the phagosomal pathogen stimulated the outgrowth of IL-12 dependent Th1 cells with superior protective capacity.

## Highlights

- Influenza and *Salmonella* induce Tfh and IL-12-independent early Th1 effector cells
- *Salmonella* but not influenza drives later outgrowth of IL-12-dependent Th1 cells
- The *Salmonella*-induced late Th1 population has protective CXCR3<sup>+</sup> and CX<sub>3</sub>CR1<sup>+</sup> cells
- *Salmonella*-induced CX<sub>3</sub>CR1<sup>+</sup> cells are cytotoxic and depend on ZEB2



## Article

# Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells

Peter D. Krueger,<sup>1,2</sup> Michael F. Goldberg,<sup>1,2,3</sup> Sung-Wook Hong,<sup>1</sup> Kevin C. Osum,<sup>1</sup> Ryan A. Langlois,<sup>1</sup> Dmitri I. Kotov,<sup>1,4</sup> Thamotharampillai Dileepan,<sup>1</sup> and Marc K. Jenkins<sup>1,5,\*</sup>

<sup>1</sup>Center for Immunology, Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455 USA

<sup>2</sup>These authors contributed equally

<sup>3</sup>Present address: BostonGene, University Office Park III, 95 Sawyer Road, Waltham, MA 02453

<sup>4</sup>Present address: 415 Life Science Addition, University of California, Berkeley, Berkeley, CA 94720

<sup>5</sup>Lead contact

\*Correspondence: [jenki002@umn.edu](mailto:jenki002@umn.edu)

<https://doi.org/10.1016/j.immuni.2021.03.006>

## SUMMARY

Interferon- $\gamma$  (IFN- $\gamma$ )-producing CD4<sup>+</sup> T helper-1 (Th1) cells are critical for protection from microbes that infect the phagosomes of myeloid cells. Current understanding of Th1 cell differentiation is based largely on reductionist cell culture experiments. We assessed Th1 cell generation *in vivo* by studying antigen-specific CD4<sup>+</sup> T cells during infection with the phagosomal pathogen *Salmonella enterica* (Se), or influenza A virus (IAV), for which CD4<sup>+</sup> T cells are less important. Both microbes induced T follicular helper (Tfh) and interleukin-12 (IL-12)-independent Th1 cells. During Se infection, however, the Th1 cells subsequently outgrew the Tfh cells via an IL-12-dependent process and formed subsets with increased IFN- $\gamma$  production, ZEB2-transcription factor-dependent cytotoxicity, and capacity to control Se infection. Our results indicate that many infections induce a module that generates Tfh and poorly differentiated Th1 cells, which is followed in phagosomal infections by an IL-12-dependent Th1 cell amplification module that is critical for pathogen control.

## INTRODUCTION


CD4<sup>+</sup> T cells use T cell antigen receptors (TCRs) to recognize major histocompatibility complex II (MHCII)-bound microbial peptides (p:MHCII) on host cells (Rudolph et al., 2006). TCR signaling causes naive CD4<sup>+</sup> T cells to proliferate and differentiate into T helper-1 (Th1), Th2, Th9, Th17, T follicular (Tfh), or peripheral regulatory T (Treg) cells depending on cytokines from cells of the innate immune system (Sun and Zhang, 2014). These specialized subsets are thought to protect their host from different infections. Th1 cells are critical for host protection from microbes that infect the phagosomes of myeloid cells (Tubo and Jenkins, 2014).

*In vitro* experimentation shows that Th1 cells form by a stepwise process in which TCR, IFN- $\gamma$  receptor, and STAT1 signaling causes expression of T-bet (Afkarian et al., 2002; Lighvani et al., 2001; Mullen et al., 2001; Schulz et al., 2009), the master transcription factor of Th1 cells (Szabo et al., 2000). As TCR signaling wanes (Schulz et al., 2009), T-bet induces the IL-12 receptor and IL-12 receptor signaling activates STAT4 (Thieu et al., 2008), which drives proliferation of the Th1 cells and enhances their T-bet expression, interferon- $\gamma$  (IFN- $\gamma$ ) production capacity, and commitment to the Th1 cell lineage (Mullen et al., 2001; Murphy and Reiner, 2002; O'Shea and Paul, 2010).

*In vivo* formation of antigen-specific Th1 cells has been studied most intensively in acute infections. These infections drive microbial p:MHCII-specific CD4<sup>+</sup> naive T cells to proliferate and form Th1 cells and two Tfh effector cell populations - CXCR5<sup>hi</sup> BCL6<sup>hi</sup> germinal center T follicular helper cells (GC-Tfh) and their CXCR5 intermediate (int) BCL6<sup>lo</sup> precursors (Ballesteros-Tato et al., 2012; Choi et al., 2011; Johnston et al., 2009; Kunzli et al., 2020; Marshall et al., 2011; Pepper and Jenkins, 2011; Yu et al., 2009). This heterogeneity is driven by STAT5 signals from IL-2 receptors favoring Th1 cells on the one hand and STAT3 signals from IL-6 and IL-21 receptors promoting Tfh cells on the other (Ballesteros-Tato et al., 2012; Johnston et al., 2012; Pepper et al., 2011; Ray et al., 2014). Ninety percent of the effector cells die after the infections are cleared leaving Th1 and Tfh-like CXCR5<sup>int</sup> memory cells (Hale et al., 2013; Kunzli et al., 2020; Marshall et al., 2011; Pepper et al., 2011).

Although these studies provide basic information on *in vivo* Th1 cell formation, their relevance to immunity is less clear because acute infections can be controlled by hosts lacking CD4<sup>+</sup> T cells (Allan et al., 1990; Baldrige et al., 1990; Ladel et al., 1994; Matloubian et al., 1994). Th1 cells have therefore also been studied *in vivo* under conditions where they are critical for pathogen control as is the case for *Salmonella enterica* serovar Typhimurium (Se) and *Mycobacterium tuberculosis* (Mtb)





(legend on next page)

infections of the macrophage phagosome (Tubo and Jenkins, 2014). In these situations, microbial p:MHCII-specific CD4<sup>+</sup> T cell populations contain very few Tfh cells and are dominated by Th1 cells (Goldberg et al., 2018; Sallin et al., 2017). Here, we compared the CD4<sup>+</sup> T cell response to acute infection with influenza A virus (IAV) to that with the phagosomal pathogen Se to better understand how Th1 cells are formed *in vivo* in a context where they are critical for immunity. We found that early on, both infections induced an equal mix of Tfh and relatively undifferentiated IL-12-independent Th1 cells that were maintained indefinitely in the case of IAV. In contrast, during Se infection, an IL-12- and ZEB2-dependent process caused the Th1 cells to outgrow the Tfh cells and acquire a more differentiated phenotype associated with enhanced IFN- $\gamma$  production, terminal differentiation, cytotoxicity, and phagosomal pathogen control. These results suggest that many infections activate a common module that generates mixed Th1 and Tfh effector cell populations, which in some infections is followed by a later IL-12-dependent module that amplifies the Th1 cell component critical for control of phagosomal pathogens.

## RESULTS

### Se infection drives greater expansion of antigen-specific CD4<sup>+</sup> T cells than IAV infection

We studied Th1 cell formation during IAV infection, a case where the infection can be cleared without CD4<sup>+</sup> T cells (Allan et al., 1990), and Se infection, where CD4<sup>+</sup> T cells play a critical role in pathogen control (Goldberg et al., 2018; Johanns et al., 2010). We chose IAV and Se bacteria engineered to express 2W (Rees et al., 1999), a well-studied immunogenic I-A<sup>b</sup>-binding peptide that is recognized by a relatively large population of naive CD4<sup>+</sup> T cells in mice that express I-A<sup>b</sup> (Moon et al., 2007). Focus on the same pre-immune population eliminated variables related to epitope stability or T cell repertoire size. Se-2W bacteria were given orally or intravenously, while IAV-2W was given intranasally. Antigens from both infections become systemic in all these cases, however, as indicated by profound T cell activation in the spleen (Goldberg et al., 2018; Turner et al., 2013).

Initial experiments were performed to assess the tempo of the CD4<sup>+</sup> T cell response to each infection. Cells from spleens and lymph nodes of infected C57BL/6 (B6) mice were stained with fluorochrome-labeled 2W:I-A<sup>b</sup> tetramer and fluorochrome antibody-labeled magnetic beads and enriched on magnetized columns as previously described (Moon et al., 2007). 2W:I-A<sup>b</sup> tetramer-binding conventional (FOXP3<sup>-</sup>) T cells were identified


by flow cytometry among the CD4<sup>+</sup> cells that bound to the columns (Figure S1). The secondary lymphoid organs of uninfected B6 mice contained about 300 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells (Figure 1A; Moon et al., 2007). By day four, the number of these cells in Se-2W-infected mice had already increased but remained at the starting number in IAV-2W-infected mice. By day seven, however, the number of 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells in IAV-2W-infected mice had also increased above the baseline. The number of 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells peaked at day seven for IAV-2W infection at 40,000 cells, and at day 10 for Se-2W infection at 800,000 cells. In both cases, the number of 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells then contracted and stabilized over the next several months as previously described for other infections (Marshall et al., 2011; Pepper et al., 2011). Thus, clonal expansion of 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells started earlier and was larger for Se-2W than IAV-2W infection.

### The Th1 cell population induced by Se infection improves its IFN- $\gamma$ production capacity and gains a CX<sub>3</sub>CR1<sup>+</sup> subset over time

We next examined the differentiation of 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells during each infection. As expected for naive T cells (Jenkins et al., 2010), the 2W:I-A<sup>b</sup>-specific cells in the secondary lymphoid organs of uninfected mice expressed low amounts of CD44 and did not express T-bet, ROR $\gamma$ t - the lineage-defining transcription factor for Th17 cells (Ivanov et al., 2006), BCL6, CXCR5, CXCR3 - the chemokine receptor for CXCL9 and CXCL10 (Groom and Luster, 2011), or CX<sub>3</sub>CR1 - the chemokine receptor for fractalkine (Figure 1B; Imai et al., 1997). After IAV-2W infection, the 2W:I-A<sup>b</sup>-specific T cells expanded enough in the secondary lymphoid organs by day seven to allow an accurate assessment of phenotype (Figure 1C). About half of the cells in the population at this time were CXCR5<sup>hi</sup> BCL6<sup>hi</sup> GC-Tfh or CXCR5<sup>int</sup> BCL6<sup>lo</sup> Tfh-like cells and the other half were CXCR5<sup>-</sup> cells that expressed T-bet, but not ROR $\gamma$ t, and CXCR3, but not CX<sub>3</sub>CR1 (Figures 1C and 1D). The IAV-2W-induced 2W:I-A<sup>b</sup>-specific population maintained this composition into the later effector period on day 10 and into the post-contraction memory phase on day 50 (Figure 1D) although the GC-Tfh population lost expression of BCL6 as previously described (Figure 1C; Hale et al., 2013; Kunzli et al., 2020; Pepper et al., 2011; Tubo et al., 2016). On day four, Se-2W-infected mice also contained an expanded 2W:I-A<sup>b</sup>-specific population in the secondary lymphoid organs consisting of about 50 percent CXCR5<sup>hi</sup> BCL6<sup>hi</sup> GC-Tfh or CXCR5<sup>int</sup> BCL6<sup>lo</sup> cells and 50 percent CXCR5<sup>-</sup> T-bet<sup>+</sup> ROR $\gamma$ t<sup>-</sup> CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> cells (Figure 1F) as in IAV-2W infected mice. The CXCR5<sup>+</sup> populations were rapidly outnumbered after

#### Figure 1. Expansion and differentiation of naive 2W:I-A<sup>b</sup>-specific T cells after infection with IAV-2W or Se-2W

- (A) Mean numbers ( $\pm$ SD) of 2W:I-A<sup>b</sup> tetramer-binding cells in the spleen and lymph nodes of B6 mice at the indicated times after infection.
- (B) Flow cytometry plots of the indicated molecules for 2W:I-A<sup>b</sup> tetramer<sup>+</sup> (left) or CXCR5<sup>-</sup> 2W:I-A<sup>b</sup> tetramer<sup>+</sup> cells (middle and right) from tetramer-enriched spleen and lymph node samples from an unimmunized B6 mouse.
- (C) Flow cytometry plots of the indicated molecules for 2W:I-A<sup>b</sup> tetramer<sup>+</sup> (left) or CXCR5<sup>-</sup> 2W:I-A<sup>b</sup> tetramer<sup>+</sup> cells (middle and right) from tetramer-enriched spleen and lymph node samples of B6 mice four, seven, 10, or 50 days after infection with IAV-2W.
- (D) Mean numbers ( $\pm$ SD) (top) or percentages (bottom) of 2W:I-A<sup>b</sup> tetramer-binding cells with the indicated phenotypes from individual mice at the indicated times after IAV-2W infection.
- (E) Flow cytometry plots of the indicated molecules for 2W:I-A<sup>b</sup> tetramer<sup>+</sup> (left) or CXCR5<sup>-</sup> 2W:I-A<sup>b</sup> tetramer<sup>+</sup> cells (middle and right) from tetramer-enriched spleen and lymph node samples of B6 mice four, seven, 10, or 50 days after infection with Se-2W.
- (F) Mean numbers ( $\pm$ SD) (top) or percentages (bottom) of 2W:I-A<sup>b</sup> tetramer-binding cells with the indicated phenotypes from individual mice at the indicated times after Se-2W infection. A-F, n  $\geq$  three mice per group/time point. See also Figures S1 and S2.



**Figure 2. IFN- $\gamma$  production by Th1 cells in IAV-2W or Se-2W infections**

(A) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from mice with the indicated infections that were not or were injected with 2W peptide two hours before analysis. IAV-2W day seven, Se-2W day four, and the day 10 pairs were analyzed on different days.

(B) Percent of IFN- $\gamma$ <sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells from individual mice ( $n \geq$  four from two independent experiments) with the indicated infections for the indicated times, two hours after injection of 2W peptide or not. Mean values on scatterplots are indicated with a horizontal bar. Values were compared using one-way ANOVA. \*\*\*\* $p < 0.0001$ ; n.s., not significant.

day four, however, by an expanding population of CXCR5<sup>-</sup> T-bet<sup>+</sup> Th1 cells, which contained a CX<sub>3</sub>CR1<sup>+</sup> subset as early as day seven and that peaked at 50 percent of the population by day 50. Thus, Th1 cells came to dominate the 2W:I-A<sup>b</sup>-specific T cell population in Se-2W-infected mice because of proliferation at a faster rate than Tfh cells after day four.

We also examined the liver because Se infection spreads to this location (Monack et al., 2004). Day 10 was chosen for this analysis because it is near the time of peak clonal expansion of 2W:I-A<sup>b</sup>-specific T cells for both infections (Figures 1D and 1F). 2W:I-A<sup>b</sup>-specific effector T cells were present in the livers of IAV-2W and Se-2W infected mice, although many more were in the latter group (Figures S2A and S2B). In IAV-2W infection, the 2W:I-A<sup>b</sup>-specific T cell population was composed exclusively of T-bet<sup>+</sup> (Figure S2C) Th1 cells most expressing CXCR3 (Figure S2A) and lacking CX<sub>3</sub>CR1 (Figures S2A and S2D). Although all the cells in the livers of Se-2W infected mice were also T-bet<sup>+</sup> Th1 cells (Figure S2C), about 40 percent of the cells expressed CX<sub>3</sub>CR1 (Figure S2D). Thus, the livers of IAV-2W or Se-2W infected mice lacked Tfh cells and contained the Th1 populations that were found in the secondary lymphoid organs.


We then measured the *in vivo* IFN- $\gamma$  production potential of the Th1 cells in the secondary lymphoid organs. As shown in Figures 2A and 2B, IFN- $\gamma$  was not detected by *ex vivo* intracellular staining in 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells four to 16 days after either infection, presumably because very few of the T cells were being stimulated *in vivo* in this time frame. An intravenous injection of 2W peptide was then used to recall IFN- $\gamma$  production (Khoruts et al., 1998). About 20 percent of the T-bet<sup>+</sup> 2W:I-A<sup>b</sup>-specific T cells in the early effector phase of each infection (day four-five for Se-2W, day seven for IAV-2W) produced IFN- $\gamma$  two hours after the 2W peptide injection (Figures 2A and 2B). A similar fraction of the T-bet<sup>+</sup> 2W:I-A<sup>b</sup>-specific T cell population in the later effector phase of the IAV-2W infection (day 10–16) had IFN- $\gamma$  production potential. In contrast, the fraction of the T-bet<sup>+</sup> 2W:I-A<sup>b</sup>-specific T cell population that was capable of

producing IFN- $\gamma$  increased to 80 percent by day seven of Se-2W-infection and remained at this fraction on days 10–16. Notably, like the T-bet<sup>+</sup> 2W:I-A<sup>b</sup>-specific T cells in Se-2W-infected mice on day four, the cells on day seven were almost all CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> (Figure 1E), indicating that this population had improved its IFN- $\gamma$  production potential between days four and seven. The fact that the day 10–16 population, which contained 80 percent IFN- $\gamma$  producing cells, was a mixture of CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CX<sub>3</sub>CR1<sup>+</sup> Th1 cells indicated that the majority of cells in both subsets could produce IFN- $\gamma$ . Together, the results indicated that only a minority of the epitope-specific CD4<sup>+</sup> effector Th1 cells induced at early times by the two different infections could produce IFN- $\gamma$ . While this pattern was maintained into the later effector phase in IAV-2W infection, the Th1 cell population that emerged in Se-2W infection during this period had increased IFN- $\gamma$  production potential.

### The Th1 cell population induced by Se infection becomes more IL-12-dependent over time

*In vitro* studies show that Th1 cell differentiation begins with IL-12-independent T-bet induction followed by IL-12- and STAT4-dependent T-bet enhancement and commitment to the Th1 cell lineage (Mullen et al., 2001; Murphy et al., 2000; Schulz et al., 2009; Thieu et al., 2008). Other studies indicate that type I IFN receptor (encoded by the *Inar1* gene) (Longhi et al., 2009), IFN- $\gamma$  receptor (Hsieh et al., 1993; Lighvani et al., 2001; Scott, 1991), and IL-18 receptor signaling (Kaplanski, 2018) can also influence Th1 cell differentiation.

We explored the role of these factors in Th1 cell differentiation beginning with IAV-2W infection. As shown in Figure 3A, 2W:I-A<sup>b</sup>-specific T cells accumulated by days seven–10 of IAV-2W infection to the same degree in mice lacking IL-12, IL-18, or type I IFN receptor, or wild-type or type I IFN receptor-deficient mice treated with neutralizing IL-12 or IFN- $\gamma$  antibodies, as they did in wild-type mice. Similarly, IL-12- (Figures 3B and 3C) or IL-18-deficiency or neutralization of IL-12 or IFN- $\gamma$  had no effect on the formation of T-bet<sup>+</sup> cells (Figure 3C), the amount of T-bet per



**Figure 3. Molecular requirements for Th1 cell formation during IAV-2W infection**

(A) Number of 2W:I-A<sup>b</sup> tetramer-binding cells from individual mice (n ≥ three from two independent experiments) of the indicated genotypes on days seven–10 of IAV-2W infection.

(B) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from IAV-2W-infected mice of the indicated genotypes.

(C–E) Percent T-bet<sup>+</sup> (C), mean fluorescence intensity of T-bet<sup>+</sup> cells (D), or percent IFN-γ<sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells two hours after peptide challenge (E) from individual mice (n ≥ three from two independent experiments) of the indicated genotypes. Mean values on scatterplots are indicated with a horizontal bar. Values in A, C–E were compared using one-way ANOVA. \*\*\*\*p < 0.0001; n.s., not significant.


cell (Figure 3D), or the capacity of T-bet<sup>+</sup> cells to produce IFN-γ after peptide challenge (Figure 3E). In contrast, type I IFN receptor-deficiency led to a two-fold reduction in the percentage of T-bet<sup>+</sup> cells in the 2W:I-A<sup>b</sup>-specific T cell population in IAV-2W-infected mice (Figures 3B and 3C), and addition of IL-12 or IFN-γ antibodies did not increase the magnitude of this defect (Figure 3C). The residual T-bet<sup>+</sup> population in IAV-2W-infected type I IFN receptor-deficient mice expressed the same amount of T-bet (Figure 3D) and contained the same 20 percent frequency of IFN-γ producing cells as the population in wild-type mice (Figure 3E). Thus, the formation of the Th1 cell population with a 20 percent component of IFN-γ-producing cells did not involve IL-12, IL-18, or IFN-γ. About half of the cells in this population, however, required type I IFN receptor to form.

We performed a similar analysis for 2W:I-A<sup>b</sup>-specific T cells present in the later effector phase of Se-2W infection. IL-12-deficient but not type I IFN receptor-deficient or IL-18-deficient mice had five-fold fewer 2W:I-A<sup>b</sup>-specific T cells than wild-type mice on day 10 after Se-2W infection (Figure 4A) indicating that IL-12, but not type I IFN receptor or IL18 was involved in the outgrowth of this population. The smaller population of 2W:I-A<sup>b</sup>-specific T cells in IL-12-deficient mice consisted of a mixture of CXCR5<sup>-</sup> T-bet<sup>+</sup> cells and CXCR5<sup>+</sup> Tfh cells, whereas the population in wild-type mice consisted mainly of CXCR5<sup>-</sup> T-bet<sup>+</sup> cells (Figures 4B and 4C). The T-bet<sup>+</sup> population in IL-12-deficient mice also expressed less T-bet per cell (Figure 4D) and lacked the CX<sub>3</sub>CR1<sup>+</sup> subset that was prominent in wild-type mice (Figure 4E). Only

about 10 percent of the T-bet<sup>+</sup> 2W:I-A<sup>b</sup>-specific T cells in IL-12-deficient Se-2W-infected mice produced IFN-γ two hours after *in vivo* peptide challenge compared to 90 percent in wild-type mice (Figure 4F). The 2W:I-A<sup>b</sup>-specific T cell populations that formed in type I IFN receptor- or IL-18-deficient Se-infected mice were indistinguishable from the T-bet<sup>high</sup> population with IFN-γ producing cells and a CX<sub>3</sub>CR1<sup>+</sup> subset that formed in wild-type mice (Figures 4C–4F). These results show that the amplification of a T-bet<sup>high</sup> population with enhanced IFN-γ production potential and a CX<sub>3</sub>CR1<sup>+</sup> subset in Se-2W-infected mice depends on IL-12 but not type I IFN receptor or IL-18.

We then used an adoptive transfer approach to determine whether the defects in Th1 cell differentiation observed in Se-infected IL-12-deficient mice were intrinsic to the T cells. Congenically marked CD4<sup>+</sup> T cells from uninfected IL-12 receptor-deficient mice were injected into wild-type mice, which were then infected with Se-2W bacteria. The phenotypes of effector T cells derived from the transferred IL-12 receptor-deficient naive cells or the wild-type naive cells of the recipient (Figure 4G) were then assessed on day 10. As expected, the wild-type population of 2W:I-A<sup>b</sup>-specific T cells of recipient origin was composed of T-bet<sup>high</sup> CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CX<sub>3</sub>CR1<sup>+</sup> Th1 cells, most of which produced IFN-γ after 2W peptide injection (Figures 4H and 4J–4M). In contrast, the IL-12 receptor-deficient donor-derived population contained a mixture of Tfh cells (Figure 4I) and a T-bet<sup>+</sup> Th1 cell population (Figures 4I and 4J) that had less T-bet per cell (Figure 4K), expressed CXCR3 but not CX<sub>3</sub>CR1 (Figures 4I and 4L), and had fewer cells that made IFN-γ after peptide challenge (Figure 4M) than the comparable wild-type population. These results show that a CD4<sup>+</sup> T cell intrinsic capacity to respond to IL-12 is required for all the features of the Th1 cell amplification process that occurs during Se infection.

Th1 cell amplification accelerates after day four of Se infection (Figures 1F), indicating that this is a critical period of IL-12



**Figure 4. Molecular requirements for Th1 cell formation during Se-2W infection**

(A) Number of 2W:I-A<sup>b</sup> tetramer-binding cells from individual mice (n ≥ five from two independent experiments) of the indicated genotypes on day 10 of Se-2W infection.

(legend continued on next page)

production. Mice were treated with IL-12 antibody beginning on day two of Se-2W infection to neutralize IL-12 during this interval and then analyzed on day seven as a test of this possibility. The 2W:I-A<sup>b</sup>-specific T cell population in IL-12 antibody-treated mice was three times smaller than that in untreated mice (Figure 5A) and consisted of an equal mixture of CXCR5<sup>+</sup> Tfh and T-bet<sup>+</sup> Th1 cells while the population in untreated mice was dominated by T-bet<sup>+</sup> Th1 cells (Figure 5B). In addition, the T-bet<sup>+</sup> cells in IL-12 antibody-treated mice expressed less T-bet per cell (Figure 5C) and a smaller fraction produced IFN- $\gamma$  after peptide injection than the comparable population in untreated mice (Figure 5D). The T-bet<sup>+</sup> population in IL-12 antibody-treated mice also contained only CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> cells, while the population in untreated mice contained this subset plus a few CX<sub>3</sub>CR1<sup>+</sup> cells (Figure 5E) as expected for the day seven time point (Figure 1F). Thus, neutralization of IL-12 beginning on day two of Se-2W infection prevented Th1 cell amplification and yielded an epitope-specific population similar to the one generated by IAV infection.

These results raised the possibility that Th1 cell amplification does not occur during IAV-2W infection because IL-12 is limited after the early phase of the infection. We tested this possibility by injecting IL-12 into mice beginning on day three of IAV-2W infection. The 2W:I-A<sup>b</sup>-specific T cell population in IL-12-treated mice was three times larger than that in untreated mice (Figure 5F) and was dominated by T-bet<sup>+</sup> cells while the population in untreated mice consisted of an equal mixture of CXCR5<sup>+</sup> Tfh and T-bet<sup>+</sup> cells (Figure 5G). In addition, the T-bet<sup>+</sup> cells in IL-12-treated mice expressed more T-bet per cell (Figure 5H) and a larger fraction produced IFN- $\gamma$  after peptide injection than the comparable population in untreated mice (Figure 5I). The T-bet<sup>+</sup> population in IL-12-treated mice also contained CX<sub>3</sub>CR1<sup>+</sup> cells, while the population in untreated mice lacked this subset (Figure 5J). Together, the results of IL-12 blockade in Se infection and IL-12 addition in IAV infection indicate that the presence of IL-12 after the early phase of infection is necessary and sufficient to generate the Th1 cell amplification program.

### CX<sub>3</sub>CR1<sup>+</sup> Th1 cells are cytotoxic and depend on the ZEB2 transcription factor

We performed bulk RNA sequencing on tetramer-purified CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CX<sub>3</sub>CR1<sup>+</sup> Th1 cells to get clues about the origin and function of the CX<sub>3</sub>CR1 Th1 cell subset. B6  $\times$  129 F1 mice, another I-A<sup>b</sup>-expressing strain, and an I-A<sup>b</sup> tetramer containing a peptide from the Se LpdA protein (LpdAp) (Karunakaran et al., 2017) were used in this case. The LpdAp:I-A<sup>b</sup>-specific T cell population in Se-infected 129 mice contains the same CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CX<sub>3</sub>CR1<sup>+</sup> Th1 cell subsets

(Goldberg et al., 2018) as the 2W:I-A<sup>b</sup>-specific T cell population in Se-2W-infected B6 mice.

About 1,000 differentially expressed genes were identified (Figure 6A). CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> cells preferentially expressed *Cxcr3*, *Il23r*, *Pecam1*, *Btla*, and *Tnfrsf4* mRNA. In contrast, CX<sub>3</sub>CR1<sup>+</sup> cells expressed more *Cx3cr1*, *S1p5r*, and *Klrg1* mRNA than CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> cells. CX<sub>3</sub>CR1<sup>+</sup> cells also expressed *Gzma*, *Prf1*, and *Fasl* encoding granzyme A, perforin, and Fas ligand, which have cytotoxic activities (Golstein and Griffiths, 2018). We therefore considered the possibility that CX<sub>3</sub>CR1<sup>+</sup> cells belonged to the cytotoxic CD4<sup>+</sup> T cell subset (Marshall and Swain, 2011; Weiskopf et al., 2015). We tested it using an *in vivo* assay, which we developed to measure 2W:I-A<sup>b</sup>-specific cytotoxic CD4<sup>+</sup> T cells (Kotov et al., 2018), and *Cd4<sup>cre</sup> Cx3cr1<sup>DTR</sup>* mice (Diehl et al., 2013), which express the simian diphtheria toxin (DT) receptor in CX<sub>3</sub>CR1<sup>+</sup> T cells and can be used to deplete this population. Splenocytes from uninfected mice were labeled with high or low concentrations of the vital dye CellTrace Violet (CTV) (Quah et al., 2013) and the cells labeled with the low concentration were pulsed with the 2W peptide. The CTV<sup>high</sup> and CTV<sup>low</sup> splenocytes were then mixed and injected into uninfected wild-type mice or day 30 Se-2W-infected wild-type or *Cd4<sup>cre</sup> Cx3cr1<sup>DTR</sup>* mice that had been treated with DT. About 60 percent of the 2W peptide-pulsed CTV<sup>low</sup> target cells were preferentially eliminated in DT-treated Se-2W-infected wild-type mice compared to the uninfected controls indicating that cytotoxic CD4<sup>+</sup> T cells were present in the former group (Figures 6B and 6C). In contrast, only 25 percent of the 2W peptide-pulsed CTV<sup>low</sup> target cells were eliminated in DT-treated Se-2W-infected *Cd4<sup>cre</sup> Cx3cr1<sup>DTR</sup>* mice, which lacked CX<sub>3</sub>CR1<sup>+</sup> T cells (Figure 6D). Thus, the CX<sub>3</sub>CR1<sup>+</sup> 2W:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells in Se-2W-infected mice have cytotoxic activity.

The RNA sequencing experiments also showed that Se-induced CX<sub>3</sub>CR1<sup>+</sup> T cells preferentially express the ZEB2 transcription factor (Figure 6A), which was reported to control terminal differentiation of CD8<sup>+</sup> cytotoxic T cells (Dominguez et al., 2015; Omilusik et al., 2015). We tested the role of ZEB2 in the formation of CX<sub>3</sub>CR1<sup>+</sup> CD4<sup>+</sup> T cells using a radiation chimera approach. Bone marrow cells from congenically-marked *Zeb2<sup>fl/fl</sup>* mice or *Cd4<sup>cre</sup> Zeb2<sup>fl/fl</sup>* mice (Omilusik et al., 2015) were injected into lethally irradiated recipients. The recipients were rested for two months to allow for development of ZEB2-deficient T cells from the *Cd4<sup>cre</sup> Zeb2<sup>fl/fl</sup>* bone marrow and wild-type T cells from the *Zeb2<sup>fl/fl</sup>* bone marrow. The chimeric mice were then infected with Se-2W bacteria and analyzed 14 days later. The ZEB2-deficient 2W:I-A<sup>b</sup>-specific T cell population was about three times smaller than the wild-type one (Figure 6E). This difference in size was associated with the preferential loss of CX<sub>3</sub>CR1<sup>+</sup>


(B) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from Se-2W-infected mice of the indicated genotypes.

(C–F) Percent T-bet<sup>+</sup> (C), mean fluorescence intensity of T-bet<sup>+</sup> cells (D), percent CX<sub>3</sub>CR1<sup>+</sup> cells (E), or IFN- $\gamma$ <sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells two hours after peptide challenge (F) from individual mice ( $n \geq$  three from two independent experiments) of the indicated genotypes.

(G) Flow cytometry plot used to identify 2W:I-A<sup>b</sup> tetramer-binding cells of recipient (CD45.1) or donor (CD45.2) origin from Se-2W-infected B6 mice that received CD4<sup>+</sup> T cells from IL-12 receptor-deficient mice.

(H and I) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells of recipient (H, wild-type) or donor (I, IL-12 receptor-deficient) origin from Se-2W-infected B6 mice that received CD4<sup>+</sup> T cells from IL-12 receptor-deficient mice.

(J–M) Percent T-bet<sup>+</sup> (J), mean fluorescence intensity of T-bet<sup>+</sup> cells (K), percent CX<sub>3</sub>CR1<sup>+</sup> cells (L), or percent IFN- $\gamma$ <sup>+</sup> cells two hours after peptide challenge (M) among wild-type or IL-12 receptor-deficient T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells from individual mice ( $n \geq$  three from two independent experiments). Values in A, C–F were compared using one-way ANOVA. Values in J–M were compared using an unpaired Student's *t* test. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . Mean values on scatterplots are indicated with a horizontal bar.



**Figure 5. Effects of IL-12 neutralization or addition on epitope-specific CD4<sup>+</sup> T cells during infections**

(A) Number of 2W:I-A<sup>b</sup> tetramer-binding cells from individual Se-2W-infected mice ( $n \geq$  six from two independent experiments) given nothing or IL-12 antibody (Ab) on days two and four of infection and analyzed on day seven.


(B) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from Se-2W-infected mice given nothing (top) or IL-12 antibody (bottom) on days two and four of infection and analyzed on day seven, with a scatterplot of the percent of T-bet<sup>+</sup> cells among 2W:I-A<sup>b</sup> tetramer-binding cells.

(C and D) Mean fluorescence intensity of T-bet<sup>+</sup> cells (C) or IFN- $\gamma$ <sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells two hours after peptide challenge (D) from individual mice ( $n \geq$  four from two independent experiments) of the indicated treatment groups.

(E) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from Se-2W-infected mice given nothing (top) or IL-12 antibody (bottom) on days two and four of infection and analyzed on day seven, with a scatterplot of the percent of CX<sub>3</sub>CR1<sup>+</sup> cells among 2W:I-A<sup>b</sup> tetramer-binding cells from the two groups.

(F) Number of 2W:I-A<sup>b</sup> tetramer-binding cells from individual IAV-2W-infected mice ( $n =$  nine from three independent experiments) given nothing or recombinant IL-12 on days three–six of infection and analyzed on day 10.

(legend continued on next page)



**Figure 6. Formation of CX<sub>3</sub>CR1<sup>+</sup> cytotoxic cells is ZEB2-dependent**

(A) Volcano plot of RNA sequencing results from LpdAp:I-A<sup>b</sup> tetramer-binding CXCR3<sup>+</sup> (open) or CX<sub>3</sub>CR1<sup>+</sup> (closed) cells from day 30 Se-infected B6 × 129 F1 mice.

(B) Flow cytometric analysis of an *in vivo* cytotoxicity assay using CTV to identify CTV<sup>lo</sup> splenic B cells pulsed with 2W peptide and CTV<sup>hi</sup> unpulsed B cells 20 hours after injection into the indicated mice.

(C) Specific cell lysis of 2W peptide-pulsed B cells in individual mice ( $n \geq 10$  per group from three independent experiments) from the indicated groups.

(D) Flow cytometry plots of T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells from day 30 Se-2W-infected mice from the indicated groups demonstrating depletion of CX<sub>3</sub>CR1<sup>+</sup> cells from DT-treated *Cd4<sup>Cre</sup> Cx3cr1<sup>DTR</sup>* mice.

(E) Number of 2W:I-A<sup>b</sup> tetramer-binding cells of wild-type (*Zeb2<sup>fl/fl</sup>*) or ZEB2-deficient (*Cd4<sup>Cre</sup> Zeb2<sup>fl/fl</sup>*) origin in day 10 Se-2W-infected chimeric mice.

(F) Flow cytometry plots of T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells of wild-type (*Zeb2<sup>fl/fl</sup>*) or ZEB2-deficient (*Cd4<sup>Cre</sup> Zeb2<sup>fl/fl</sup>*) origin in day 10 Se-2W-infected chimeric mice, with a scatterplot of the percent of CX<sub>3</sub>CR1<sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells. Values were compared using an unpaired Student's *t* test (\*\*\*\* $p < 0.0001$ ) and were derived from two–three independent experiments. The horizontal lines represent the mean for each group.

T cells (Figure 6F). Thus, the component of the Th1 amplification pathway that forms CX<sub>3</sub>CR1<sup>+</sup> cytotoxic cells depends on ZEB2.

### IL-12 amplified Th1 cells are more protective


Earlier work has shown that CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>−</sup> Th1 cells with robust IFN- $\gamma$  production capacity and CX<sub>3</sub>CR1<sup>+</sup> Th1 cells can

both protect naive hosts from Se infection after adoptive transfer (Goldberg et al., 2018). The fact that these are the subsets produced by the Th1 cell amplification process raised the possibility that the purpose of this module is to produce T cells that control phagosomal pathogens. This possibility was tested by comparing the protective capacity of T cell populations that

(G) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding cells from IAV-2W-infected mice given nothing (top) or recombinant IL-12 (bottom) on days three–six of infection and analyzed on day 10, with a scatterplot of the percent T-bet<sup>+</sup> cells among 2W:I-A<sup>b</sup> tetramer-binding cells.

(H and I) Mean fluorescence intensity of T-bet<sup>+</sup> cells (H) or IFN- $\gamma$ <sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells two hours after peptide challenge (I) from individual mice ( $n \geq 3$  from two independent experiments) of the indicated treatment groups.

(J) Flow cytometry plots of T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells from Se-2W-infected mice given nothing (top) or recombinant IL-12 (bottom) on days three–six of infection and analyzed on day 10, with a scatterplot of the percent of CX<sub>3</sub>CR1<sup>+</sup> cells among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding cells. Values were compared using an unpaired Student's *t* test. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ ; n.s., not significant. Mean values on scatterplots are indicated with a horizontal bar.



**Figure 7. Amplified Th1 cells provide superior protection from Se infection**

(A) CFU in the indicated organs from individual B6 mice (n = six per group from three independent experiments) that received CD4<sup>+</sup> T cells from the indicated sources.

(B) Flow cytometry plots used to identify 2W:I-A<sup>b</sup> tetramer-binding T cells of donor (CD45.1) or recipient (CD45.2) origin in B6 mice that received CD4<sup>+</sup> T cells from day seven Se-2W-infected (top) or IL-12 antibody-treated day seven Se-2W-infected mice (bottom). Some of the recipients of each type of donor T cell population were also treated with IL-12 antibody. IL-12 antibody treatment of the recipient mice had no discernable effect so the data for each donor population were pooled.

(C) Number of 2W:I-A<sup>b</sup> tetramer-binding T cells from individual day seven Se-2W-infected (top) or IL-12 antibody-treated day seven Se-2W-infected mice (bottom) (n = six per group from three independent experiments) after three days in Se-2W-infected recipients.

(D) Flow cytometry plots of 2W:I-A<sup>b</sup> tetramer-binding T cells from day seven Se-2W-infected or IL-12 antibody-treated day seven Se-2W-infected mice after three days in Se-2W-infected recipients, with scatterplots of percent T-bet<sup>+</sup> cells.

(E and F) Mean fluorescence intensity of T-bet<sup>+</sup> cells (E) and percent CX<sub>3</sub>CR1<sup>+</sup> cells (F) among T-bet<sup>+</sup> 2W:I-A<sup>b</sup> tetramer-binding from individual mice (n = six from three independent experiments). Values in A were compared using one-way ANOVA. Values in C-F were compared using an unpaired Student's t test. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; ns, not significant. Mean values on scatterplots are indicated with a horizontal bar.

had undergone Th1 cell amplification to ones that had not due to IL-12 blockade. Mice were infected with Se-2W bacteria and some were treated with IL-12 antibody. CD4<sup>+</sup> T cells were purified from the secondary lymphoid organs of both groups seven days after infection and small samples were stained with 2W:I-A<sup>b</sup> tetramer to assess the effectiveness of the block. As expected, the 2W:I-A<sup>b</sup>-specific T cells proliferated in unblocked mice and formed a large population dominated by T-bet<sup>high</sup> CXCR3<sup>+</sup> cells with a minority CX<sub>3</sub>CR1<sup>+</sup> subset, while the population in IL-12 antibody-treated mice was smaller and contained Tfh cells and T-bet<sup>+</sup> CXCR3<sup>+</sup> Th1 cells with less T-bet per cell and very few CX<sub>3</sub>CR1<sup>+</sup> cells (Figures 5A–5E). The frequency of 2W:I-A<sup>b</sup> tetramer-binding cells in each sample was then used to transfer populations containing the same number of 2W:I-A<sup>b</sup>

tetramer-binding cells into separate groups of naive mice, thereby correcting for the differences in 2W and presumably other Se epitope-specific T cells in the two groups. Some of the recipients of CD4<sup>+</sup> T cells from IL-12-treated donors were also treated with IL-12 antibody. The recipient mice and controls that did not receive CD4<sup>+</sup> T cells were then infected with Se and viable bacteria in the spleen and liver were measured three days later.

Control naive mice that did not receive CD4<sup>+</sup> T cells had about 10<sup>5</sup> Se-2W bacteria in their spleens and livers (Figure 7A). In contrast, mice that received CD4<sup>+</sup> T cells from day seven Se-2W-infected donors contained ten-fold fewer bacteria in both organs, indicating that the transferred T cells had reduced the bacterial burden. Mice that received CD4<sup>+</sup> T cells from IL-12

antibody-treated Se-2W-infected donors reduced the bacteria in the spleen three-fold compared to the controls and not at all in the liver whether or not the recipient mice were treated with IL-12 antibody. Thus, Se epitope-specific populations that had undergone Th1 cell amplification protected the spleen and especially the liver better than Se epitope-specific populations that had not undergone Th1 cell amplification.

The transferred T cell populations were monitored at the end of the three-day challenge period to see if their phenotype in the spleen had changed. The transferred populations were much larger than the recipient's population, which had only begun a primary response (Figure 7B). The transferred 2W:I-A<sup>b</sup>-specific T cell population from unblocked mice was larger than the one from IL-12 blocked mice (Figure 7C), indicating that the former proliferated more than the latter during the challenge period. Both populations, however, retained their pre-transfer phenotypes - the population from unblocked donors was dominated by T-bet<sup>high</sup> CXCR3<sup>+</sup> cells with some CX<sub>3</sub>CR1<sup>+</sup> cells (Figures 7D–7F), while the population from IL-12 blocked donors contained Tfh cells (Figure 7D), CXCR3<sup>+</sup> Th1 cells with less T-bet per cell (Figure 7E), and very few CX<sub>3</sub>CR1<sup>+</sup> cells (Figure 7F). Thus, the superior protective capacity of the population from unblocked Se-infected mice was associated with the presence of T-bet<sup>high</sup> CXCR3<sup>+</sup> cells and CX<sub>3</sub>CR1<sup>+</sup> cells. These results demonstrate that the amplified Th1 cell population provides better protection from Se infection than the earlier mixed population of Th1 and Tfh cells.

## DISCUSSION

The goal of this study was identification of the mechanisms that govern Th1 cell differentiation during infection with a phagosomal pathogen (Se) that is controlled by this lymphocyte subset. The epitope-tagged Se and IAV microbes studied here caused CD4<sup>+</sup> naive T cells to form early effector cell populations composed of a balanced mixture of Tfh cells and Th1 cells as observed for *Listeria monocytogenes*, Lymphocytic Choriomeningitis Virus, and other IAV infections (Ballesteros-Tato et al., 2012; Choi et al., 2011; Johnston et al., 2009; Kunzli et al., 2020; Marshall et al., 2011; Pepper and Jenkins, 2011; Yu et al., 2009). Tfh and non-Tfh effector cells are also induced by *Streptococcus pyogenes* infection (Linehan et al., 2015) and immunization with house dust mite extract (Hondowicz et al., 2016) but in these cases the non-Tfh cells are Th17 and Th2 cells, respectively. Contemporaneous bifurcation of Th and non-Tfh cells thus appears to be a common activation module evolved to provide helper cells for both humoral and cell-mediated immunity. It results from a tug of war in which early effector cells that receive strong IL-2 receptor-mediated STAT5 signals induce BLIMP1, which represses BCL6, and become non-Tfh cells, while effector cells that receive weak IL-2 receptor-mediated STAT5 signals express BCL6 and become Tfh cells (Crotty, 2011). The fate of the non-Tfh cells is then determined by type 1, type 2, or type 17 innate immune system cytokines (Zhu et al., 2010). Although it is not totally clear what causes individual effector cells to become Tfh or non-Tfh cells, TCR signal strength is likely involved since it controls IL-2 receptor expression (Kotov et al., 2019; Krishnamoorthy et al., 2017).

Our results on *in vivo* generated Th1 cells are consistent with a two-step model of Th1 cell differentiation that emerges from cell

culture experiments in the early 2000s (Mullen et al., 2001; Schulz et al., 2009). This model posited a first step in which TCR signaling stimulates IL-12-independent expression of T-bet and the IL-12 receptor, resulting in a Th1 cell population dominated by cells with weak IFN- $\gamma$  production capacity. These cells then proceed to a second step in which IL-12 receptor signaling activates STAT4, which enhances T-bet expression, IFN- $\gamma$  production capacity, and commitment to the Th1 lineage.

Our results indicate that the epitope-specific Th1 cells generated during IAV infection complete the first step of Th1 cell differentiation but do not proceed to the second. This contention is based on our findings that Th1 cells that formed during IAV infection did not depend on IL-12 as reported in studies of other viruses (Monteiro et al., 1998; Oxenius et al., 1999; Schijns et al., 1998; Xing, 2001), and only a minority had the potential to produce IFN- $\gamma$ . Although the formation of about half of these Th1 cells depends on type I IFN receptor as reported previously (Longhi et al., 2009), many other Th1 cells formed in the absence of type I IFN receptor, IL-12, IL-18, or IFN- $\gamma$ . These type I IFN receptor-independent Th1 cells may form by default in response to TCR and IL-2 receptor-driven STAT5 signals when innate immune system cytokines that drive Th2 or Th17 cell differentiation are absent. The type I IFN receptor-dependent and type I IFN receptor-independent Th1 cells in IAV-infected mice may not undergo Th1 cell amplification because acute IAV infection does not sustain IL-12 production long enough. Our observation that Th1 cell amplification occurs in IAV-infected mice given exogenous IL-12 on day three and reports that certain chronic viral infections induce CX<sub>3</sub>CR1<sup>+</sup> Th1 cells (Batista et al., 2020; De Giovanni et al., 2020; Weiskopf et al., 2015) are consistent with this possibility. Th1 cell populations containing only a minority of IFN- $\gamma$ -producing cells may be advantageous to the host during IAV infection by providing a limited anti-viral effect without causing immunopathology. This contention is supported by reports that late IL-12 production actually *increases* viral burden (Ishikawa et al., 2016; Kostense et al., 1998; van der Sluijs et al., 2006), whereas IFN- $\gamma$  deficiency reduces immunopathology during primary IAV infection (Califano et al., 2018).

Our studies show that Se infection induces the bifurcation module and generates early Tfh and Th1 effector cells. In this case, however, the Th1 cells undergo the IL-12-dependent second step of the Th1 cell differentiation process. A likely scenario for this progression is that sustained IL-12 production and IL-12 receptor signaling causes the CXCR3<sup>+</sup> Th1 population generated during the bifurcation module to proliferate more than Tfh cells, increase expression of T-bet and IFN- $\gamma$  production capacity, and generate CX<sub>3</sub>CR1<sup>+</sup> progeny. The fact that Th1 cells proliferate longer than Tfh cells during the same infection has been described by Craft and colleagues and attributed to enhanced mTOR activation (Ray et al., 2015). The outgrowth of Th1 cells may contribute to poor germinal center formation during Se infection in addition to the directly suppressive effects of IL-12 on Tfh cell differentiation (Elsner and Shlomchik, 2019). Th1 outgrowth was associated with the formation of CX<sub>3</sub>CR1<sup>+</sup> cells, which have been shown in other systems to arise from CXCR3<sup>+</sup> precursors (Chu et al., 2016; Dominguez et al., 2015; Omilusik et al., 2015) by an IL-12-dependent mechanism (Sallin et al., 2017). Our results indicate that the generation of CX<sub>3</sub>CR1<sup>+</sup> cells depends on the ZEB2 transcription factor, which is likely induced by STAT4 binding to the *Zeb2* gene

(Wei et al., 2010). ZEB2 turns on expression of several E-proteins (Omlusik et al., 2015), which may then stimulate production of CX<sub>3</sub>CR1, perforin, granzyme B, Fas ligand, and commit cells to the cytotoxic differentiation program.

The CD4<sup>+</sup> T cell population in day seven Se-infected mice, which had begun the Th1 cell amplification process, provided better protection of the spleen and liver than a population stuck in the bifurcation module. This difference was likely related to the fact that the amplified Th1 cell population contained a greater number of IFN- $\gamma$ -producing CXCR3<sup>+</sup> cells and had a population of CX<sub>3</sub>CR1<sup>+</sup> cytotoxic cells in both of these organs. In another study, we have shown that CXCR3<sup>+</sup> Th1 cells are positioned around Se-containing granulomas in the spleen and liver and control the infection via an IFN- $\gamma$ -dependent mechanism (Goldberg et al., 2018). Thus, one function of the Th1 cell amplification program is to generate cells that can position themselves at granuloma sites of persistent infection and produce the key cytokine needed for macrophages to kill the intracellular bacteria they harbor. Another function of this program is to generate CX<sub>3</sub>CR1<sup>+</sup> cytotoxic Th1 cells, which also participate in control of Se infection, although to a lesser degree than CXCR3<sup>+</sup> Th1 cells (Goldberg et al., 2018). CX<sub>3</sub>CR1<sup>+</sup> Th1 cells may kill Se-infected macrophages harboring bacteria.

Although Th1 cell amplification benefits the host by controlling phagosomal pathogens, it may create a risk for more pathogenic viral infection as evidenced by the observation that people with tuberculosis had an increased risk of death during the 1918 H1N1 influenza pandemic (Noymer and Garenne, 2000). Phagosomal infections may produce a basal amount of IL-12, which could drive amplification of virus-specific Th1 cells capable of causing acute tissue damage and acute respiratory distress syndrome.

## LIMITATIONS OF STUDY

The fact that we only analyzed two pathogens is a limitation of our study. Studies of many other pathogens will be needed to establish that initial contemporaneous generation of Tfh and non-Tfh cells is a universal property of the CD4<sup>+</sup> T cell response. Another limitation in our study is that it did not identify the mechanisms that generate IL-12 independent Th1 cells during module one. Lastly, additional studies independently targeting the two subsets of module two Th1 cells will be needed to determine their independent roles in protection against phagosomal pathogens.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENT MODEL AND SUBJECT DETAILS
- METHOD DETAILS

- Mice
- Infections
- Tetramers
- Cell enrichment and flow cytometry
- Intracellular cytokine detection
- Antibody neutralization and recombinant protein administration
- RNA-sequencing
- *In vivo* cytotoxicity assay
- Se protection experiments
- Bone marrow chimeras

## ● QUANTIFICATION AND STATISTICAL ANALYSIS

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.immuni.2021.03.006>.

## ACKNOWLEDGMENTS

This work was funded by grants from the US National Institutes of Health R01 AI039614 and R01 AI103760 to M.K.J., T32 AI83196 to D.I.K., and T32 HL007062 to P. D. K. and M.F.G. The authors acknowledge Jennifer Walter and Charles Elwood for their help with maintaining mice and Juan Abrahante Llorens for his help with analysis of RNA sequence data.

## AUTHOR CONTRIBUTIONS

Conceptualization, P.D.K., M.K.J.; Methodology, P. D. K., M.F.G., M.K.J., D.I.K., R. A. L., T.D.; Formal Analysis, P.D.K., M.K.J.; Investigation, P.D.K., S.W.H., K.C.O., M.F.G.; Writing-Original Draft, P.D.K., M.K.J.; Writing-Review & Editing, P.D.K., M.K.J.; Visualization, P.D.K., M.K.J.; Funding Acquisition, M.K.J.; Supervision, M.K.J.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

## INCLUSION AND DIVERSITY

We worked to ensure sex balance in the selection of non-human subjects.

Received: May 1, 2020

Revised: December 31, 2020

Accepted: March 8, 2021

Published: March 26, 2021

## REFERENCES

- Afkarian, M., Sedy, J.R., Yang, J., Jacobson, N.G., Cereb, N., Yang, S.Y., Murphy, T.L., and Murphy, K.M. (2002). T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4<sup>+</sup> T cells. *Nat. Immunol.* 3, 549–557.
- Allan, W., Tabi, Z., Cleary, A., and Doherty, P.C. (1990). Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4<sup>+</sup> T cells. *J. Immunol.* 144, 3980–3986.
- Baldrige, J.R., Barry, R.A., and Hinrichs, D.J. (1990). Expression of systemic protection and delayed-type hypersensitivity to *Listeria monocytogenes* is mediated by different T-cell subsets. *Infect. Immun.* 58, 654–658.
- Ballesteros-Tato, A., León, B., Graf, B.A., Moquin, A., Adams, P.S., Lund, F.E., and Randall, T.D. (2012). Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. *Immunity* 36, 847–856.
- Batista, N.V., Chang, Y.H., Chu, K.L., Wang, K.C., Girard, M., and Watts, T.H. (2020). T cell-intrinsic CX3CR1 marks the most differentiated effector CD4(+) T cells, but is largely dispensable for CD4(+) T cell responses during chronic viral infection. *Immunohorizons* 4, 701–712.

- Benoun, J.M., Peres, N.G., Wang, N., Pham, O.H., Rudisill, V.L., Fogassy, Z.N., Whitney, P.G., Fernandez-Ruiz, D., Gebhardt, T., Pham, Q.M., et al. (2018). Optimal protection against *Salmonella* infection requires noncirculating memory. *Proc. Natl. Acad. Sci. USA* **115**, 10416–10421.
- Califano, D., Furuya, Y., Roberts, S., Avram, D., McKenzie, A.N.J., and Metzger, D.W. (2018). IFN- $\gamma$  increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. *Mucosal Immunol.* **11**, 209–219.
- Choi, Y.S., Kageyama, R., Eto, D., Escobar, T.C., Johnston, R.J., Monticelli, L., Lao, C., and Crotty, S. (2011). ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. *Immunity* **34**, 932–946.
- Chu, H.H., Chan, S.W., Gosling, J.P., Blanchard, N., Tsitsiklis, A., Lythe, G., Shastri, N., Molina-Paris, C., and Robey, E.A. (2016). Continuous effector CD8(+) T cell production in a controlled persistent infection is sustained by a proliferative intermediate population. *Immunity* **45**, 159–171.
- Crotty, S. (2011). Follicular helper CD4 T cells (TFH). *Annu. Rev. Immunol.* **29**, 621–663.
- De Giovanni, M., Cutillo, V., Giladi, A., Sala, E., Maganuco, C.G., Medaglia, C., Di Lucia, P., Bono, E., Cristofani, C., Consolo, E., et al. (2020). Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4<sup>+</sup> T cells. *Nat. Immunol.* **21**, 321–330.
- Diehl, G.E., Longman, R.S., Zhang, J.X., Breart, B., Galan, C., Cuesta, A., Schwab, S.R., and Littman, D.R. (2013). Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. *Nature* **494**, 116–120.
- Dominguez, C.X., Amezcua, R.A., Guan, T., Marshall, H.D., Joshi, N.S., Kleinstein, S.H., and Kaech, S.M. (2015). The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. *J. Exp. Med.* **212**, 2041–2056.
- Elsner, R.A., and Shlomchik, M.J. (2019). IL-12 blocks Tfh cell differentiation during *Salmonella* infection, thereby contributing to germinal center suppression. *Cell Rep.* **29**, 2796–2809.e5.
- Goldberg, M.F., Roeske, E.K., Ward, L.N., Pengo, T., Dileepan, T., Kotov, D.I., and Jenkins, M.K. (2018). *Salmonella* persist in activated macrophages in T cell-sparse granulomas but are contained by surrounding CXCR3 ligand-positioned Th1 cells. *Immunity* **49**, 1090–1102.
- Golstein, P., and Griffiths, G.M. (2018). An early history of T cell-mediated cytotoxicity. *Nat. Rev. Immunol.* **18**, 527–535.
- Groom, J.R., and Luster, A.D. (2011). CXCR3 ligands: redundant, collaborative and antagonistic functions. *Immunol. Cell Biol.* **89**, 207–215.
- Hale, J.S., Youngblood, B., Latner, D.R., Mohammed, A.U., Ye, L., Akondy, R.S., Wu, T., Iyer, S.S., and Ahmed, R. (2013). Distinct memory CD4<sup>+</sup> T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. *Immunity* **38**, 805–817.
- Hemann, E.A., Green, R., Turnbull, J.B., Langlois, R.A., Savan, R., and Gale, M., Jr. (2019). Interferon- $\lambda$  modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus. *Nat. Immunol.* **20**, 1035–1045.
- Hoiseth, S.K., and Stocker, B.A. (1981). Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* **291**, 238–239.
- Hondowicz, B.D., An, D., Schenkel, J.M., Kim, K.S., Steach, H.R., Krishnamurthy, A.T., Keitany, G.J., Garza, E.N., Fraser, K.A., Moon, J.J., et al. (2016). Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma. *Immunity* **44**, 155–166.
- Hsieh, C.S., Macatonia, S.E., O'Garra, A., and Murphy, K.M. (1993). Pathogen-induced Th1 phenotype development in CD4<sup>+</sup>  $\alpha$   $\beta$ -TCR transgenic T cells is macrophage dependent. *Int. Immunol.* **5**, 371–382.
- Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiya, H., Schall, T.J., and Yoshie, O. (1997). Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. *Cell* **91**, 521–530.
- Ishikawa, H., Ino, S., Sasaki, H., Fukui, T., Kohda, C., and Tanaka, K. (2016). The protective effects of intranasal administration of IL-12 given before influenza virus infection and the negative effects of IL-12 treatment given after viral infection. *J. Med. Virol.* **88**, 1487–1496.
- Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., and Littman, D.R. (2006). The orphan nuclear receptor ROR $\gamma$  directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* **126**, 1121–1133.
- Jenkins, M.K., Chu, H.H., McLachlan, J.B., and Moon, J.J. (2010). On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands. *Annu. Rev. Immunol.* **28**, 275–294.
- Johanns, T.M., Ertelt, J.M., Rowe, J.H., and Way, S.S. (2010). Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent *Salmonella* infection. *PLoS Pathog.* **6**, e1001043.
- Johnston, R.J., Poholek, A.C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A.L., Craft, J., and Crotty, S. (2009). Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* **325**, 1006–1010.
- Johnston, R.J., Choi, Y.S., Diamond, J.A., Yang, J.A., and Crotty, S. (2012). STAT5 is a potent negative regulator of TFH cell differentiation. *J. Exp. Med.* **209**, 243–250.
- Kaplanski, G. (2018). Interleukin-18: Biological properties and role in disease pathogenesis. *Immunol. Rev.* **281**, 138–153.
- Karunakaran, K.P., Yu, H., Jiang, X., Chan, Q., Goldberg, M.F., Jenkins, M.K., Foster, L.J., and Brunham, R.C. (2017). Identification of MHC-bound peptides from dendritic cells infected with *Salmonella enterica* strain SL1344: Implications for a nontyphoidal *Salmonella* vaccine. *J. Proteome Res.* **16**, 298–306.
- Khoruts, A., Mondino, A., Pape, K.A., Reiner, S.L., and Jenkins, M.K. (1998). A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. *J. Exp. Med.* **187**, 225–236.
- Kostense, S., Sun, W.H., Cottey, R., Taylor, S.F., Harmeling, S., Zander, D., Small, P.A., Jr., and Bender, B.S. (1998). Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice. *Antiviral Res.* **38**, 117–130.
- Kotov, D.I., Kotov, J.A., Goldberg, M.F., and Jenkins, M.K. (2018). Many Th cell subsets have Fas ligand-dependent cytotoxic potential. *J. Immunol.* **200**, 2004–2012.
- Kotov, D.I., Mitchell, J.S., Pengo, T., Ruedl, C., Way, S.S., Langlois, R.A., Fife, B.T., and Jenkins, M.K. (2019). TCR affinity biases Th cell differentiation by regulating CD25, Eef1e1, and Gbp2. *J. Immunol.* **202**, 2535–2545.
- Krishnamoorthy, V., Kannanganat, S., Maisenschein-Cline, M., Cook, S.L., Chen, J., Bahroos, N., Sievert, E., Corse, E., Chong, A., and Sciammas, R. (2017). The IRF4 gene regulatory module functions as a read-write integrator to dynamically coordinate T helper cell fate. *Immunity* **47**, 481–497.e7.
- Kunzli, M., Schreiner, D., Pereboom, T.C., Swarnalekha, N., Litzler, L.C., Lotscher, J., Ertuna, Y.I., Roux, J., Geier, F., Jakob, R.P., et al. (2020). Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity. *Sci. Immunol.* **5**, <https://doi.org/10.1126/sciimmunol.aay5552>.
- Ladel, C.H., Flesch, I.E., Arnoldi, J., and Kaufmann, S.H. (1994). Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on *Listeria monocytogenes* infection. *J. Immunol.* **153**, 3116–3122.
- Lee, P.P., Fitzpatrick, D.R., Beard, C., Jessup, H.K., Lehar, S., Makar, K.W., Pérez-Melgosa, M., Sweetser, M.T., Schlissel, M.S., Nguyen, S., et al. (2001). A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity* **15**, 763–774.
- Lighvani, A.A., Frucht, D.M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B.D., Nguyen, B.V., Gadina, M., Sher, A., Paul, W.E., and O'Shea, J.J. (2001). T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. *Proc. Natl. Acad. Sci. USA* **98**, 15137–15142.
- Linehan, J.L., Dileepan, T., Kashem, S.W., Kaplan, D.H., Cleary, P., and Jenkins, M.K. (2015). Generation of Th17 cells in response to intranasal

- infection requires TGF- $\beta$ 1 from dendritic cells and IL-6 from CD301b+ dendritic cells. *Proc. Natl. Acad. Sci. USA* **112**, 12782–12787.
- Longhi, M.P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A.M., Colonna, M., and Steinman, R.M. (2009). Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. *J. Exp. Med.* **206**, 1589–1602.
- Magram, J., Connaughton, S.E., Warriar, R.R., Carvajal, D.M., Wu, C.Y., Ferrante, J., Stewart, C., Sarmiento, U., Faherty, D.A., and Gately, M.K. (1996). IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. *Immunity* **4**, 471–481.
- Marshall, N.B., and Swain, S.L. (2011). Cytotoxic CD4 T cells in antiviral immunity. *J. Biomed. Biotechnol.* **2011**, 954602.
- Marshall, H.D., Chandele, A., Jung, Y.W., Meng, H., Poholek, A.C., Parish, I.A., Rutishauser, R., Cui, W., Kleinstein, S.H., Craft, J., and Kaech, S.M. (2011). Differential expression of Ly6C and T-bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection. *Immunity* **35**, 633–646.
- Matloubian, M., Concepcion, R.J., and Ahmed, R. (1994). CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. *J. Virol.* **68**, 8056–8063.
- Monack, D.M., Bouley, D.M., and Falkow, S. (2004). Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFN $\gamma$  neutralization. *J. Exp. Med.* **199**, 231–241.
- Monteiro, J.M., Harvey, C., and Trinchieri, G. (1998). Role of interleukin-12 in primary influenza virus infection. *J. Virol.* **72**, 4825–4831.
- Moon, J.J., Chu, H.H., Pepper, M., McSorley, S.J., Jameson, S.C., Kedl, R.M., and Jenkins, M.K. (2007). Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. *Immunity* **27**, 203–213.
- Mullen, A.C., High, F.A., Hutchins, A.S., Lee, H.W., Villarino, A.V., Livingston, D.M., Kung, A.L., Cereb, N., Yao, T.-P., Yang, S.Y., and Reiner, S.L. (2001). Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. *Science* **292**, 1907–1910.
- Müller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M., and Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. *Science* **264**, 1918–1921.
- Murphy, K.M., and Reiner, S.L. (2002). The lineage decisions of helper T cells. *Nat. Rev. Immunol.* **2**, 933–944.
- Murphy, K.M., Ouyang, W., Farrar, J.D., Yang, J., Ranganath, S., Asnagli, H., Afkarian, M., and Murphy, T.L. (2000). Signaling and transcription in T helper development. *Annu. Rev. Immunol.* **18**, 451–494.
- Nelson, R.W., McLachlan, J.B., Kurtz, J.R., and Jenkins, M.K. (2013). CD4+ T cell persistence and function after infection are maintained by low-level peptide:MHC class II presentation. *J. Immunol.* **190**, 2828–2834.
- Noymer, A., and Garenne, M. (2000). The 1918 influenza epidemic's effects on sex differentials in mortality in the United States. *Popul. Dev. Rev.* **26**, 565–581.
- O'Shea, J.J., and Paul, W.E. (2010). Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. *Science* **327**, 1098–1102.
- Omilusik, K.D., Best, J.A., Yu, B., Goossens, S., Weidemann, A., Nguyen, J.V., Seuntjens, E., Stryjewska, A., Zweier, C., Roychoudhuri, R., et al. (2015). Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. *J. Exp. Med.* **212**, 2027–2039.
- Oxenius, A., Karrer, U., Zinkernagel, R.M., and Hengartner, H. (1999). IL-12 is not required for induction of type 1 cytokine responses in viral infections. *J. Immunol.* **162**, 965–973.
- Pepper, M., and Jenkins, M.K. (2011). Origins of CD4(+) effector and central memory T cells. *Nat. Immunol.* **12**, 467–471.
- Pepper, M., Pagán, A.J., Igyártó, B.Z., Taylor, J.J., and Jenkins, M.K. (2011). Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. *Immunity* **35**, 583–595.
- Quah, B.J., Wijesundara, D.K., Ranasinghe, C., and Parish, C.R. (2013). Fluorescent target array T helper assay: a multiplex flow cytometry assay to measure antigen-specific CD4+ T cell-mediated B cell help in vivo. *J. Immunol. Methods* **387**, 181–190.
- Ray, J.P., Marshall, H.D., Laidlaw, B.J., Staron, M.M., Kaech, S.M., and Craft, J. (2014). Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. *Immunity* **40**, 367–377.
- Ray, J.P., Staron, M.M., Shyer, J.A., Ho, P.C., Marshall, H.D., Gray, S.M., Laidlaw, B.J., Araki, K., Ahmed, R., Kaech, S.M., and Craft, J. (2015). The Interleukin-2-mTORC1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. *Immunity* **43**, 690–702.
- Rees, W., Bender, J., Teague, T.K., Kedl, R.M., Crawford, F., Marrack, P., and Kappler, J. (1999). An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. *Proc. Natl. Acad. Sci. USA* **96**, 9781–9786.
- Rudolph, M.G., Stanfield, R.L., and Wilson, I.A. (2006). How TCRs bind MHCs, peptides, and coreceptors. *Annu. Rev. Immunol.* **24**, 419–466.
- Sallin, M.A., Sakai, S., Kauffman, K.D., Young, H.A., Zhu, J., and Barber, D.L. (2017). Th1 differentiation drives the accumulation of intravascular, non-protective CD4 T cells during tuberculosis. *Cell Rep.* **18**, 3091–3104.
- Schijns, V.E., Haagmans, B.L., Wierda, C.M., Kruithof, B., Heijnen, I.A., Alber, G., and Horzinek, M.C. (1998). Mice lacking IL-12 develop polarized Th1 cells during viral infection. *J. Immunol.* **160**, 3958–3964.
- Schulz, E.G., Mariani, L., Radbruch, A., and Höfer, T. (2009). Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. *Immunity* **30**, 673–683.
- Scott, P. (1991). IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. *J. Immunol.* **147**, 3149–3155.
- Sun, B., and Zhang, Y. (2014). Overview of orchestration of CD4+ T cell subsets in immune responses. *Adv. Exp. Med. Biol.* **841**, 1–13.
- Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., and Glimcher, L.H. (2000). A novel transcription factor, T-bet, directs Th1 lineage commitment. *Cell* **100**, 655–669.
- Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., and Akira, S. (1998). Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* **8**, 383–390.
- Thieu, V.T., Yu, Q., Chang, H.C., Yeh, N., Nguyen, E.T., Sehra, S., and Kaplan, M.H. (2008). Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. *Immunity* **29**, 679–690.
- Tube, N.J., and Jenkins, M.K. (2014). CD4+ T Cells: guardians of the phagosome. *Clin. Microbiol. Rev.* **27**, 200–213.
- Tube, N.J., Fife, B.T., Pagan, A.J., Kotov, D.I., Goldberg, M.F., and Jenkins, M.K. (2016). Most microbe-specific naive CD4+ T cells produce memory cells during infection. *Science* **351**, 511–514.
- Turner, D.L., Bickham, K.L., Farber, D.L., and Lefrançois, L. (2013). Splenic priming of virus-specific CD8 T cells following influenza virus infection. *J. Virol.* **87**, 4496–4506.
- van der Sluijs, K.F., van Elden, L.J., Xiao, Y., Arens, R., Nijhuis, M., Schuurman, R., Florquin, S., Jansen, H.M., Lutter, R., and van der Poll, T. (2006). IL-12 deficiency transiently improves viral clearance during the late phase of respiratory tract infection with influenza A virus in mice. *Antiviral Res.* **70**, 75–84.
- Wei, L., Vahedi, G., Sun, H.W., Watford, W.T., Takatori, H., Ramos, H.L., Takahashi, H., Liang, J., Gutierrez-Cruz, G., Zang, C., et al. (2010). Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. *Immunity* **32**, 840–851.
- Weiskopf, D., Bangs, D.J., Sidney, J., Kolla, R.V., De Silva, A.D., de Silva, A.M., Crotty, S., Peters, B., and Sette, A. (2015). Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. *Proc. Natl. Acad. Sci. USA* **112**, E4256–E4263.

Wu, C., Wang, X., Gadina, M., O'Shea, J.J., Presky, D.H., and Magram, J. (2000). IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. *J. Immunol.* *165*, 6221–6228.

Xing, Z. (2001). Breach of IL-12 monopoly in the initiation of type 1 immunity to intracellular infections: IL-12 is not required. *Cell. Mol. Biol.* *47*, 689–694.

Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M., Linterman, M., Zheng, L., Simpson, N., et al. (2009). The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity* *31*, 457–468.

Zhu, J., Yamane, H., and Paul, W.E. (2010). Differentiation of effector CD4 T cell populations (\*). *Annu. Rev. Immunol.* *28*, 445–489.

## STAR★METHODS

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
CD90.2 - Brilliant Ultraviolet 395 (clone 53-2.1)	BD Biosciences	Cat# 565257, RRID:AB_2739136
CD4 - Brilliant Ultraviolet 496 (clone GK1.5)	BD Biosciences	Cat# 564667, RRID:AB_2722549
CD44 - Brilliant Violet 510 (clone IM7)	BD Biosciences	Cat# 563114, RRID:AB_2738011
Bcl6 - PE (clone K112-91)	BD Biosciences	Cat# 561522, RRID:AB_10717126
RORγT - Brilliant Biolet 786 (clone Q31-378)	BD Biosciences	Cat# 564723, RRID:AB_2738916
CXCR3 - Brilliant Violet 421 (clone CXCR3-173)	BD Biosciences	Cat# 566283, RRID:AB_2739657
IFNγ - Brilliant Violet 650 (clone XMG1.2)	BD Biosciences	Cat# 563854, RRID:AB_2738451
CXCR5 - Brilliant Ultraviolet 395 (clone 2G8)	BD Biosciences	Cat# 563980, RRID:AB_2738521
CXCR5 - Brilliant Violet 650 (clone L138D7)	Biolegend	Cat# 145517, RRID:AB_2562453
CX3CR1 - Brilliant Violet 605 (clone SA011F11)	Biolegend	Cat# 149027, RRID: AB_2565937
T-bet - PE-Cy7 (clone 4B10)	Biolegend	Cat# 644824, RRID:AB_2561761
TER-119 - Biotin (clone TER-119)	Biolegend	Cat# 116204, RRID:AB_313705
CD45.2 - Brilliant Violet 786 (clone 104)	Biolegend	Cat# 109839, RRID:AB_2562604
F4/80 - Biotin (clone BM8)	Biolegend	Cat# 123106, RRID:AB_893501
NK-1.1 - Biotin (clone PK136)	Biolegend	Cat# 108704, RRID:AB_313391
CD62L - Biotin (MEL-14)	Biolegend	Cat# 104403, RRID:AB_313090
CD45.1 - PerCP-Cy5.5 (clone A20)	ThermoFisher	Cat# 45-0453-82, RRID:AB_1107003
CD45R (B220) - APC-eFluor780 (clone RA3-6B2)	ThermoFisher	Cat# 47-0452, RRID:AB_1518810
CD11b - APC-eFluor 780 (clone M1/70)	ThermoFisher	Cat# 47-0112, RRID:AB_1603193
CD11c - APC-eFluor 780 (clone N418)	ThermoFisher	Cat# 47-0114, RRID:AB_1548652
F4/80 - APC-eFluor 780 (clone BM8)	ThermoFisher	Cat# 47-4801, RRID: AB_1548745
FOXP3 - AF488 (clone FJK-16 s)	ThermoFisher	Cat# 53-5773-82, RRID:AB_763537
T-bet - PE (clone eBio4B10)	ThermoFisher	Cat# 12-5825-82, RRID:AB_925761
CD45R (B220) - Biotin (clone RA3-6B2)	Tonbo Biosciences	Cat# 30-0452, RRID:AB_2621644
CD8a - Biotin (clone 53-6.7)	Tonbo Biosciences	Cat# 30-0081, RRID:AB_2621638
Ly-6G (GR1) - Biotin (clone RB6-8C5)	Tonbo Biosciences	Cat# 30-5931, RRID:AB_2621652
CD11c - Biotin (clone N418)	Tonbo Biosciences	Cat# 30-0114, RRID:AB_2621640
CD11b - Biotin (clone M1/70)	Tonbo Biosciences	Cat# 30-0112, RRID:AB_2621639
InVivoMAb anti-mouse FcγII/III CD16/CD32 (clone 2.4G2)	BioXcell	Cat# BE0307, RRID:AB_2736987
InVivoMAb anti-mouse IL-12p40 (clone C17.8)	BioXcell	Cat# BE0051, RRID:AB_1107698
InVivoMAb anti-mouse IFNγ (clone XMG1.2)	BioXcell	Cat# BE0055, RRID: AB_1107694
<b>Bacterial and Virus Strains</b>		
Influenza A/PR/8/34 virus 2W	<a href="#">Hemann et. al., 2019</a>	R. Langlois, Univ. of Minnesota
<i>Salmonella enterica</i> : serovar Typhimurium: strain SL1344	<a href="#">Hoiseith and Stocker, 1981</a>	B. Cookson, Univ. of Washington
<i>Salmonella enterica</i> : serovar Typhimurium: strain SL1344-2W	<a href="#">Nelson et al., 2013</a>	M. Jenkins Univ. of Minnesota
<i>Salmonella enterica</i> : serovar Typhimurium: strain BRD509-2W	<a href="#">Benoun et al., 2018</a>	S. McSorley, Univ. of California-Davis
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Histodenz	Milipore sigma	Cat# 66108-95-0
PhycoLink Streptavidin-Allophycocyanin	Prozyme	Cat# PJ27S
123count eBeads Counting Beads	ThermoFisher	Cat# 01-1234-42
UltraComp eBeads Compensation Beads	ThermoFisher	Cat# 01-2222-42
Streptomycin Sulfate	ThermoFisher	Cat# 11860-038
Kanamycin Sulfate	ThermoFisher	Cat# 11815-032

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Dulbecco's PBS	ThermoFisher	Cat# 14190144
RNAlater™ Stabilization Solution	ThermoFisher	Cat# AM7020
Mouse IL-12 p70 Recombinant Protein	ThermoFisher	Cat# 14-8121-80
RPMI1640, L-glutamine	ThermoFisher	Cat# 11875119
Fetal Bovine Serum	Omega Scientific	Cat# FB-12
2W peptide (EAWGALANWAVDSA)	GenScript	N/A
MacConkey Agar, Granulated	HIMEDIA	Cat# GMH081
EasySep Streptavidin RapidSpheres	STEMCELL Technologies	Cat# 50001
Ghost Dye Red 780	Tonbo	Cat# 13-0865
Brefeldin A Solution (1,000X)	Biolegend	Cat# 420601
Permeabilization Buffer	Tonbo	Cat# TNB-1213-L150
2W:I-A <sup>b</sup> biotinylated monomer	<a href="#">Moon et. al., 2007</a>	N/A
LpdAp:I-A <sup>b</sup> biotinylated monomer	<a href="#">Goldberg et. al., 2018</a>	N/A

**Critical Commercial Assays**

CellTrace™ Violet Cell Proliferation Kit	ThermoFisher	C34557
EasySep Mouse APC Positive Selection Kit II	STEMCELL Technologies	Cat# 17681
RNeasy Mini Kit	QIAGEN	Cat# 74104
FOXP3/Transcription Factor Staining Buffer Set	ThermoFisher	Cat# 00-5523-00

**Experimental Models: Cell Lines**

Drosophila S2 cells	ThermoFisher	Cat# R690-07
---------------------	--------------	--------------

**Experimental Models: Organisms/Strains**

Mouse: C57BL/6Ncr (B6)	NCI/Charles River	Strain Code 556
Mouse: B6.Ly5.1/Cr (CD45.1)	NCI/Charles River	Strain Code 564
Mouse: 129X1/SvJ (129)	The Jackson Laboratory	Cat# 000691
Mouse: B6 × 129 F1	This Paper	N/A
Mouse: B6.129S1- <i>Il12b</i> <sup>tm1Jm/J</sup>	The Jackson Laboratory	Cat# 002693
Mouse: B6.129S2- <i>Ifnar1</i> <sup>tm1Agt/Mmjax</sup>	The Jackson Laboratory	Cat# 32045-JAX
Mouse: B6.129P2- <i>Il18</i> <sup>tm1Aki/J</sup>	The Jackson Laboratory	Cat# 004130
Mouse: B6.129S1- <i>Il12rb2</i> <sup>tm1Jm/J</sup>	The Jackson Laboratory	Cat# 003248
Mouse: B6N.129P2- <i>Cx3cr1</i> <sup>tm3(DTR)Litt/J</sup>	The Jackson Laboratory	Cat# 025629
Mouse: Tg(Cd4-cre)1CwiBfluJ	The Jackson Laboratory	Cat# 017336
Mouse: Cd4 <sup>cre</sup> CX3CR1 <sup>dtr</sup> × 129	This Paper	N/A
Mouse: CD45.1.2 Cd4 <sup>cre</sup> Zeb2 <sup>fl/fl</sup> bone marrow	Ananda Goldrath	N/A
Mouse: CD45.1.2 Zeb2 <sup>fl/fl</sup> bone marrow	Ananda Goldrath	N/A

**Software and Algorithms**

FlowJo v. 10	TreeStar	<a href="https://www.flowjo.com">https://www.flowjo.com</a>
Hisat2 v2.1.0	Public domain	<a href="http://daehwankimlab.github.io/hisat2/download/">http://daehwankimlab.github.io/hisat2/download/</a>
CLC Genomics Workbench	QIAGEN	<a href="https://digitalinsights.qiagen.com/">https://digitalinsights.qiagen.com/</a>
Prism 8	GraphPad	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>
Trimmomatic	Public domain	<a href="http://www.usadellab.org/cms/?page=trimmomatic">http://www.usadellab.org/cms/?page=trimmomatic</a>

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marc K. Jenkins ([jenki002@umn.edu](mailto:jenki002@umn.edu)).

### Materials availability

Mouse lines used in this study can be purchased, produced by breeding commercially available strains, or obtained from the donating lab(s) referenced. All additional reagents developed in the study will be made available from the Lead Contact.

### Data and code availability

The RNA sequencing results related to Figure 6A have been deposited in GEO at the NCBI with accession number GSE168300.

## EXPERIMENT MODEL AND SUBJECT DETAILS

Mice were housed in a specific pathogen-free facility at the University of Minnesota, and experiments were conducted according to federal and institutional guidelines and with the approval of the University of Minnesota Institutional Animal Care and Use Committee. 6- to 12-week-old, male and female, age and sex-matched mice were used for all experiments.

## METHOD DETAILS

### Mice

C57BL/6 (B6), B6.SJL-*Ptprc*<sup>a</sup> *Pep3*<sup>b</sup>/BoyJ (CD45.1), B6.129S1-*Il12b*<sup>tm1Jm/J</sup> (*Il12b*<sup>-/-</sup>) (Magram et al., 1996), B6.129S2-*Ifnar1*<sup>tm1Agt/</sup> *Mmjax* (*Ifnar1*<sup>-/-</sup>) (Müller et al., 1994), B6.129P2-*Il18*<sup>tm1Aki/J</sup> (*Il18*<sup>-/-</sup>) (Takeda et al., 1998), B6;129S1-*Il12rb2*<sup>tm1Jm/J</sup> (*Il12rb2*<sup>-/-</sup>) (Wu et al., 2000), B6N.129P2-*Cx3cr1*<sup>tm3(DTR)Litt/J</sup> (Diehl et al., 2013), Tg(*Cd4-cre*)1Cwi/BfluJ (Lee et al., 2001), and 129X1/SvJ (129) mice were used. B6 mice were bred to 129 mice to produce B6 × 129 F1 mice. B6N.129P2-*Cx3cr1*<sup>tm3(DTR)Litt/J</sup> mice were crossed to Tg(*Cd4-cre*)1Cwi/BfluJ, then crossed to 129 to produce *Cd4*<sup>Cre</sup> *Cx3cr1*<sup>DTR</sup> mice. CD45.1.2 *Cd4*<sup>Cre</sup> *Zeb2*<sup>fl/fl</sup> and *Zeb2*<sup>fl/fl</sup> bone marrow cells were provided by Kyla Omilusik and Ananda Goldrath at the University of California-San Diego. The data in all the figures came from mice on the B6 genetic background except for Figures 6A, 6B, and 6D, which contain data from B6 × 129 F1 and *Cd4*<sup>Cre</sup> *Cx3cr1*<sup>DTR</sup> 129 mice, respectively.

### Infections

Mice were injected intravenously with 2 × 10<sup>4</sup> CFU Se-2W (AroA-deficient *Se* bacteria expressing 2W) (Benoun et al., 2018), or inoculated intranasally with 40 PFU of IAV-2W (influenza A/PR/8/34 virus expressing 2W) (Hemann et al., 2019). B6 × 129 F1 mice were given 10<sup>8</sup> CFU of Se-SL1344 (Hoiseh and Stocker, 1981) orally for the RNA sequencing experiments. B6 × 129 F1 and *Cd4*<sup>Cre</sup> *Cx3cr1*<sup>DTR</sup> mice were infected orally with Se-SL1344-2W (Nelson et al., 2013) for *in vivo* cytotoxicity experiments.

### Tetramers

Biotin-labeled I-A<sup>b</sup> molecules containing the 2W (EAWGALANWAVDSA) or LpdA (HYFDPKVIPI) peptides covalently attached to the I-A<sup>b</sup> beta chain were produced with I-A<sup>b</sup> alpha chains in *Drosophila melanogaster* S2 cells, then purified and tetramerized with streptavidin allophycocyanin (APC) as described previously (Moon et al., 2007).

### Cell enrichment and flow cytometry

Tetramer-based cell enrichment was performed as previously described (Moon et al., 2007). Livers were perfused with Dulbecco's PBS via the portal vein until fully blanched. Intrahepatic mononuclear cells were purified on a 21% Histodenz gradient after centrifugation at 1250 × g for 20 minutes without braking. Single cell suspensions of pooled spleens and lymph nodes or liver preparations were stained for one hour at room temperature with APC-conjugated peptide:I-A<sup>b</sup> tetramers and BV650- or BUV395-conjugated CXCR5 antibodies, BV421-conjugated CXCR3 and BV605 conjugated CX<sub>3</sub>CR1 antibodies. Cells were enriched using EasySep Mouse APC Positive Selection kits according to the manufacturer's instructions. Enriched samples were stained for 20 min at 4°C with fluorophore-conjugated antibodies specific for: CD4, CD90.2, B220, CD11b, CD11c, F4/80, CD44, and in some cases CD45.2 and CD45.1. Cell viability was assessed using GhostDye Red 780. For analysis of the expression of transcription factors, stained cells were fixed and permeabilized with the FDXP3/Transcription Factor Staining Buffer Set according to the manufacturer's instructions. Cells were stained overnight at 4°C with fluorophore-conjugated antibodies against: FDXP3, T-bet, RORγt or BCL6. Cells were counted and analyzed by flow cytometry with counting beads on a Fortessa (BD) flow cytometer. Data were analyzed using FlowJo software.

### Intracellular cytokine detection

Infected mice were injected intravenously with 200 μg of 2W peptide in Dulbecco's PBS two hours before harvest. Spleen and lymph nodes were isolated in the presence of brefeldin A and stained according to methods described above. Cells were treated with the FDXP3/Transcription Factor Staining Buffer Set according to the manufacturer's instructions and stained overnight at 4°C with BV650-conjugated IFN-γ antibody.

### Antibody neutralization and recombinant protein administration

IL-12p40 was neutralized *in vivo* by the intravenous injection of 1 mg of mAb C17.8 on days two and four post Se-2W infection or on days three and five post IAV-2W infection. IFN-γ was neutralized *in vivo* by the intravenous injection of 1 mg of mAb XMG1.2 on days

three and five post IAV-2W infection. Recombinant mouse IL-12p70 was administered *in vivo* by intravenous injection of 60 ng each on days three, four, five, and six post IAV-2W infection.

### RNA-sequencing

Spleens and lymph nodes were harvested from B6 × 129 F1 mice 30 days after oral infection with  $10^8$  CFU Se-SL1344 bacteria. LpdAp:I-A<sup>b</sup>-specific CD4<sup>+</sup> T cells were purified using tetramer enrichment, and labeled with antibodies against mouse CD90.2, CD4, CD44, CXCR3, and CX<sub>3</sub>CR1 (all described above) for additional purification by cell sorting. Five thousand-50,000 LpdAp:I-A<sup>b</sup>-specific CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CXCR3<sup>-</sup> CX<sub>3</sub>CR1<sup>+</sup> cells from four mice were sorted separately into RNeasy lysis buffer and RNA was purified using the QIAGEN RNeasy Plus micro spin column purification kit according to the manufacturer's instructions. RNA integrity was confirmed using an Agilent Bioanalyzer and Dual-indexed Clontech Stranded Total RNA Pico Mammalian libraries were prepared by the University of Minnesota Genomics Center. The libraries were then pooled and sequenced in 0.5 lanes of an Illumina HiSeq 2500 High-output 2x50-bp paired-end run using v4 chemistry. FastQ paired-end reads, averaging 16 million per sample, were trimmed using Trimmomatic v0.33 using a three-bp sliding-window from the 3' prime end. Raw sequence data were quality controlled using FastQC and mapped to the GRCm38 (mm10) mouse genome assembly using Hisat2 v2.1.0. Differentially expressed genes between CXCR3<sup>+</sup> CX<sub>3</sub>CR1<sup>-</sup> and CXCR3<sup>-</sup> CX<sub>3</sub>CR1<sup>+</sup> populations were identified by applying a negative binomial distribution to the raw read counts using CLC Genomics Work Bench software (QIAGEN). The list of differentially expressed genes was then filtered using an absolute fold change of two and an FDR corrected p value < 0.05 as a minimal cut-off for further analysis.

### In vivo cytotoxicity assay

Splenocytes were suspended in PBS ( $3 \times 10^7$  cells per ml) and incubated at 37°C for 10 minutes in 2 μM (hi) or 0.4 μM (lo) CellTrace™ Violet (CTV), which was quenched by adding RPMI 1640 with 10% FBS. CTV<sup>lo</sup> cells were incubated for 1 hour at 37°C in RPMI 1640 with 10% FBS containing 10 μg/mL 2W peptide and then washed to remove free peptide. CTV<sup>hi</sup> and CTV<sup>lo</sup> cells were mixed at a 1:1 ratio, and  $2 \times 10^7$  total cells were injected intravenously into individual mice. The recipient mice were sacrificed 20 hours later and flow cytometry was performed to determine the CTV<sup>lo</sup>/CTV<sup>hi</sup> ratio of B220<sup>+</sup> B cells in the target cell population (Kotov et al., 2018). Specific lysis =  $100 - (\text{CTV ratio in experimental mice} / \text{CTV ratio in naive mice}) \times 100$ .

### Se protection experiments

CD4<sup>+</sup> T cells were purified from spleen and lymph node cell suspensions from B6 CD45.1<sup>+</sup> mice seven days after Se-2W infection with or without IL-12 antibody treatment on days two and four, using CD4 negative selection. A small sample from each group was stained with fluorophore-conjugated 2W:I-A<sup>b</sup> tetramer and CD4, CD44, CXCR5, CXCR3, and CX<sub>3</sub>CR1 antibodies and analyzed by flow cytometry to confirm the effectiveness of the IL-12 block and to determine the frequency of 2W:I-A<sup>b</sup> tetramer-binding T cells. The frequency values were used to equalize the number of 2W:I-A<sup>b</sup> tetramer-binding T cells in the two samples. Suspensions containing  $2 \times 10^5$  2W:I-A<sup>b</sup> tetramer-binding T cells were then injected into naive B6 CD45.2<sup>+</sup> mice. The recipient mice or controls that did not receive T cells were subsequently infected intravenously with Se-2W bacteria. Three days later, single cell suspensions of spleens and livers were plated on MacConkey Agar and bacterial colonies were counted the following day. A portion of the spleen samples was subjected to the 2W:I-A<sup>b</sup> tetramer enrichment procedure described above with addition of CD45.1 and CD45.2 antibodies to the staining panel. The number of the 2W:I-A<sup>b</sup> tetramer-binding cells and their phenotypes were determined as described above.

### Bone marrow chimeras

Bone marrow cells were harvested from femurs and tibias. Five million each of CD45.1<sup>+</sup> CD45.2<sup>+</sup> *Zeb2<sup>fl/fl</sup>* or CD45.1<sup>+</sup> CD45.2<sup>+</sup> *Cd4<sup>cre</sup>* *Zeb2<sup>fl/fl</sup>* bone marrow cells were injected into lethally irradiated (1,100 rads, split dose) CD45.1<sup>+</sup> mice.

### QUANTIFICATION AND STATISTICAL ANALYSIS

The statistical tests mentioned in the figure legends were performed using Prism software.